Appeals court approves sweeping abortion pill restrictions, teeing up SCOTUS showdown
The decision, which applies to both states like Louisiana that ban abortion and states that allow the procedure, restores the FDA’s prior policy mandating that patients only obtain the drug in person from a physician. It is arguably the biggest rollback in access to abortion since the Supreme Court’s 2022 ruling overturning Roe v. Wade.
Read more at Politico
5th Circuit Pulls a 5th Circuit on Abortion Pill
“While this is not the final word on the case, this decision represents the most sweeping threat to abortion since the overturning of Roe v. Wade,” Kelly Baden, vice president for public policy at the Guttmacher Institute, said in a statement. “If allowed to stand, it would severely restrict access to mifepristone in every state, including those where abortion is broadly legal and where voters have acted to protect abortion rights.”
Read more at Talking Points Memo
Court restricts abortion access across the US by blocking the mailing of mifepristone
“This is going to affect patients’ access to abortion and miscarriage care in every state in the nation,” said Julia Kaye, an ACLU lawyer. “When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most.”
Read more at National Public Radio, Inc.